Summarized by Masters of Longevity from PR Newswire.
The company secured funding to advance radiopharmaceuticals toward clinical development.
Key Takeaways
- Eli Radiopharma completed a nearly RMB 400 million round.
- The funding will advance preclinical and early clinical programs.
- This financing has not established clinical safety or efficacy.
